# Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)

> **NCT03273452** · PHASE2 · UNKNOWN · sponsor: **Qingdao University** · enrollment: 30 (estimated)

## Conditions studied

- Angioimmunoblastic T-cell Lymphoma

## Interventions

- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT03273452
- **Lead sponsor:** Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-01
- **Primary completion:** 2019-02
- **Final completion:** 2019-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03273452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03273452, "Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03273452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*